Sibutramine Stats & Data

Withdrawn from many markets (e.g., U.S., Canada) in 2010 after increased nonfatal myocardial infarction and stroke were observed in high-risk patients; anyone with existing cardiovascular disease, arrhythmia, or uncontrolled hypertension should avoid it entirely. Once-daily morning dosing was used clinically; avoid same-day redosing because active metabolites persist for 14–24 h and cumulatively load the cardiovascular system. Expect measurable increases in heart rate and small BP rises on average; stop and seek care for chest pain, severe headache, palpitations, or marked BP elevations. Risk of serotonin syndrome increases if combined with MAOIs or other serotonergic agents; do not use within 14 days of an MAOI and avoid serotonergic combinations. Sibutramine and/or analogs are frequently found adulterating “slimming” teas, coffees, and capsules; treat any such product as potentially mislabeled—use only products confirmed by accredited labs or avoid entirely. Rare cases of drug-induced liver injury have been reported; avoid if you have active liver disease and stop if you develop pruritus, dark urine, jaundice, or right‑upper‑quadrant pain. Because it can cause insomnia, dose early in the day and avoid other stimulants (including heavy caffeine); maintain hydration, particularly with exercise or hot environments. Metabolized mainly by CYP3A4; strong inhibitors may raise exposure and strong inducers may reduce efficacy—be cautious and monitor for BP/HR or adverse changes. Discontinuation after use is commonly followed by rebound appetite and weight regain; if discontinuing therapeutic use, plan behavioral support and nutrition in advance rather than escalating dose.